Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/19/24
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024GlobeNewsWire • 03/13/24
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesGlobeNewsWire • 02/12/24
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellGlobeNewsWire • 01/23/24
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialGlobeNewsWire • 12/09/23
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?Zacks Investment Research • 12/07/23
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 11/21/23
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Conference Call TranscriptSeeking Alpha • 11/08/23
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionGlobeNewsWire • 11/02/23
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesGlobeNewsWire • 11/01/23
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023GlobeNewsWire • 10/31/23
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDAGlobeNewsWire • 09/06/23
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/08/23
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023GlobeNewsWire • 08/01/23
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)GlobeNewsWire • 07/06/23
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International ConferenceGlobeNewsWire • 06/29/23
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant LymphomaGlobeNewsWire • 06/15/23